Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome

Abroad (travel likely)Recruiting

Conditions

Irritable Bowel Syndrome (IBS) · Irritable Bowel Syndrome of Diarrhea Type (IBS-D)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • University Hospitals Leuven (UZ Leuven), Leuven, Belgium

    Contact: Study coordinator (Jan Tack)
  • Hôpital Avicenne, Bobigny, France

    Contact: Study coordinator (Jean Marc Sabaté)
  • CHU de Rouen, Rouen, France

    Contact: Study coordinator (Chloè Melchior)
  • IRCCS Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola, Bologna, BO, Italy

    Contact: Study coordinator (Giovanni Barbara)
  • IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Milan, Italy

    Contact: Study coordinator (Maurizio Vecchi)
  • AOU Federico II di Napoli, Naples, Italy

    Contact: Study coordinator (Giovanni Sarnelli)
  • Azienda Ospedale Università Padova, Padova, Italy

    Contact: Study coordinator (Edoardo Vincenzo Savarino)
  • Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

    Contact: Study coordinator (Michele Di Stefano)
  • Azienda Ospedaliero Universitaria Pisana (AOUP), Pisa, Italy

    Contact: Study coordinator (Massimo Bellini)
  • S. Andrea University Hospital, Roma, Italy

    Contact: Study coordinator (Bruno Annibale)
  • Hospital Universitario Vall d´Hebron, Barcelona, Spain

    Contact: Study coordinator (Javier Santos)
  • Hospital Universitario Ramón y Cajal, Madrid, Spain

    Contact: Study coordinator (Carlos Teruel Sanchez-Vegazo)